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Introduction: The present study was designed to isolate Fucoidan from Sargassum wightii 
Greville and to evaluate its in-vitro anti cataract potential against galactose induced cataract 
in isolated goat lenses. 
Methods: Fucoidan was isolated from S. wightii Greville and its sulfate content was estimated 
through barium chloride method. Isolated goat lenses were divided into 5 groups as group-I 
(normal control- vehicle treated), group-II (disease control- galactose treated 55 mM), group-
III (galactose 55 mM + standard-ascorbic acid 20 µg/mL), group-IV (galactose 55 mM + 
Fucoidan-20 µg/mL) and group-V (galactose 55 mM + Fucoidan 40 µg/mL) and incubated for 
72 hours, respectively, and subjected to biochemical estimations. The opacity of lenses was also 
noted prior to biochemical estimation. 
Results: The percentage yield of isolated Fucoidan was found to be 0.65%. The extent 
of sulfation in the isolated Fucoidan was found to be as high as 33%. In high-performance 
thin-layer chromatography (HPTLC) studies, Peak 3 with Rf value of 0.18 matched with the 
standard D-glucose Rf value. Galactose induced cataractous lenses showed significant oxidative 
stress when compared to normal lenses whereas treatment with Fucoidan 20 and 40 µg/mL 
significantly combated oxidative stress and prevented the development of cataract when 
compared to cataractous lenses. The results obtained with the treatment of Fucoidan were dose 
dependant and comparable to standard.
Conclusion: The present study substantiates the claim of anti-cataract potential of Fucoidan, 
which may be correlated to its anti-oxidant property.
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A B S T R A C T
Introduction
Cataract is one of the main reasons for the cause of 
blindness worldwide. Due to cataract, approximately 19 
billion people are visionless in the world (1). It leads to 
opacification of the eye lens and impairs vision. Alteration 
in some biochemical processes such as oxidative 
stress, altered epithelial metabolism, phase transition, 
calpain-induced proteolysis, calcium accumulation, and 
cytoskeletal loss are related to the development of cataract 
(2). Though the cause of cataract is not fully understood, 
the major mechanism involved in the development of 
cataract is oxidative damage to the constituents of the eye 
lens (1).
Cataract is accompanied by alterations in antioxidant 
system such as catalase (CAT), superoxide dismutase 
(SOD), glutathione peroxidase (GPx) and reduced 
glutathione (GSH) (3). It is estimated that there will be 
a rise in total number of persons with cataract to 30.1 
million worldwide by 2020 (4). World Health Organization 
(WHO) launched Vision 2020, to eliminate cataract 
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as priority diseases (5). Therefore, there is an urge for 
pharmacological intervention to maintain transparency 
of the crystalline lens. A large number of herbal drugs 
such as Camellia sinensis, Ocimum sanctum, soybean and 
lycopene are reported to offer protection against cataracts 
with their antioxidant properties (4).
Sargassum wightii Greville is one of the important species 
belonging to the genus Sargassum. It is widely distributed 
in the southern coasts of Tamilnadu, India and many parts 
of Asia (6). It has been traditionally used in the Chinese 
medicine and wide range of bioactive properties has 
been reported from this species (7-13). This genus is an 
ideal target for investigating presence of biomolecules for 
various medical and industrial applications (14). 
Fucoidan is a sulfated polysaccharide which is commonly 
found in most of the seaweeds (15). The medicinal 
benefits of seaweed are mainly due to the presence of 
sulfated polysaccharides such as Fucoidan (16,17). Recent 
researches on Fucoidan have been broadly positive in 
support of its medical benefits (18). The term Fucoidan 
is generally used to describe the family of polysaccharides 
such as L-fucose as one of the major monosaccharides, 
which are highly sulfated and contain varying amounts 
of galactose, glucuronic acid and xylose and several other 
major constituents (19).
Fucoidan has recently been reported to possess a wide range 
of bioactivities (20) including anti-coagulant (21,22), anti-
cancer (23-26), anti-inflammatory (27) neuroprotective 
(28) antioxidant and antibacterial properties (19,29). The 
effectiveness of these activities is related to the chemical 
composition of Fucoidan, mainly due to its high degree of 
sulfation (30,31).
Studies have proved that Fucoidan is non-toxic, non-
allergenic, and it has no negative effects on the human 
body. This statement is further supported by the fact that 
nutraceutical and food supplements containing Fucoidan 
have been marketed for several years with no known 
adverse effects (32).
The aim of the present study was to isolate and characterize 
Fucoidan from Sargassum wightii Greville and to evaluate 
its in vitro anti-cataract potential against galactose induced 
cataract in isolated goat lenses.
Materials and Methods
Isolation of Fucoidan
Twenty-five grams of coarsely powdered sample of S. 
wightii was taken and 500 mL of ethanol was added. The 
mixture was subjected to mechanical stirring for 12 hours 
at room temperature and centrifuged at 2000 rpm for 10 
minutes. The mixture was then centrifuged and the residue 
was dried at room temperature. To 5 g of residue 100 mL 
of distilled water was added and stirred at 65˚C for 1 hour. 
Then it was centrifuged at 10,000 rpm for 10 minutes. 
The supernatant was collected and 1% CaCl2 was added 
and the mixture was kept at 4˚C overnight to precipitate 
alginic acid. The solution was then centrifuged at 10,000 
rpm for 10 minutes and the supernatant was collected. 
To the supernatant, ethanol 99% was added to attain the 
concentration of 30% and kept 4˚C for 4 hours. Further 
the solution was centrifuged at 10,000 rpm for 10 minutes 
and the supernatant was collected. To the supernatant, 
ethanol 99% was added to attain the concentration of 70% 
ethanol and kept at 4˚C overnight. Fucoidan was obtained 
through filtration and percentage yield was calculated 
(33,34).
Determination of sulfate content in Fucoidan
Sulfate content of isolated Fucoidan was determined 
using BaCl2. Conditioning reagent was prepared adding 
50 mL glycerol, 30 mL of HCl, 300 mL of deionised 
water, 100 mL of isopropyl alcohol and NaCl, stirring 
mechanically overnight. Fifteen milligrams of dried 
Fucoidan was taken in separate test tubes containing 5 
mL of 4M HCl and subjected to hydrolysis at 100˚C for 2 
hours. Potassium sulfate in the range of 200-1000 µg/mL 
was used as standard. To the hydrolysed sample solution, 
15 mL of deionised water was added followed by 5 mL 
of conditioning reagent. Then the mixture was subjected 
to mechanical stirring at constant speed. Further 0.3 g of 
BaCl2 was added and stirred for 1 minute and the mixture 
was allowed to stand for 4-6 minutes for precipitation of 
BaSO4. The absorbance was measured at 420 nm using 
water as blank (32).
HPTLC studies
Fucoidan (30 mg/mL) was taken and hydrolysed with 6M 
trifluoroacetic acid at 100˚C for 24 hours. Centrifugation 
of hydrolysate was done at 7380 rpm for 10 minutes and 
obtained supernatant was used for high-performance thin-
layer chromatography (HPTLC) studies. Fifty milliliters 
of n-butyl alcohol/acetic acid/water (6:3:1) was used as 
solvent system. D-glucose (standard – monosaccharide) 
was used as standard (35).
Four milliliters of the standard and test solution were 
loaded as 6 mm band length in the 5 x 10 Silica gel 
60F254 TLC plate using Hamilton syringe and CAMAG 
LINOMAT 5 instrument. The samples loaded plates 
were kept in TLC twin trough developing chamber and 
developed in the respective mobile phase up to 90 mm. 
The developed plate was sprayed with respective spray 
reagent (5% sulphuric acid in methanol) and heated until 
the spot appeared. The plate was photo-documented at 
day light and UV 425 nm using CAMAG REPROSTAR 
3 chamber. The developed plate was dried by hot air to 
evaporate solvents from the plate. The plate was kept in 
CAMAG REPROSTAR 3 and captured the images at white 
light (425 nm). 
The details of HPTLC were as follows: Plate: Aluminium 
plate pre-coated with silica gel GF254; Thickness: 0.2 mm 
plate size: 5 × 10 cm; Sample application: 4.0 µL; Solvent 
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system: n-butyl alcohol: glacial acetic acid: water (6: 3: 
1); Detection: UV (425 nm); Instrument: CAMAG TLC 
Scanner 3 and LINOMAT- V. CAMAG TLC Scanner 3 
and LINOMAT-V densitometric evaluation system with 
WINCATS software was used for scanning of thin layer 
chromatogram objects in reflectance or transmission 
mode by absorbance 425 nm respectively (36).
Anti-cataract activity
Experimental design
The anti-cataract potential of Fucoidan was evaluated in 
isolated goat lenses. The fresh goat lenses were procured 
from local slaughter house. Thirty lenses (Figure 1) 
were divided into 5 groups with 6 lenses in each group 
(Figure 2). For inducing cataract, the goat lenses were 
incubated with Galactose (55 mM) for 72 hours (15). 
Opacification of lenses were evaluated on a graph paper 
and counting number of squares visible through the lenses 
macroscopically (3). 
The lenses were grouped as:
•	 Group 1 - Normal control (vehicle treated)
•	 Group 2 - Disease control (galactose 55 mM treated 
cataractous lenses)
•	 Group 3 - Standard drug treated (galactose 55 mM + 
ascorbic acid-20 µg/mL)
•	 Group 4 - Fucoidan low dose treated (galactose 55 
mM + 20 µg/mL)
•	 Group 5 - Fucoidan high dose treated (galactose 55 
mM + 40 µg/mL)
Vehicle treated non-cataractous lenses were used as 
normal control (group-I). In group II, cataract was 
induced by incubating the lenses with galactose 55 mM 
for 72 hours, which served as positive control. Group-
III was incubated simultaneously with galactose 55 mM 
and standard drug ascorbic acid. Group IV and V were 
incubated simultaneously with galactose 55 mM and 
Fucoidan 20, 40 µg/mL, respectively, for 72 hours.
The dose range of Fucoidan was chosen after a pilot study 
conducted with the range of 10–80 µg/mL. Streptomycin 
was added to all groups of lenses to avoid any microbial 
contamination during incubation.
After incubation, the lenses were visualised and their 
degree of opacity was noted. For MDA estimation, the 
homogenate was prepared using 10% (w/v) 0.1 M Tris–
HCl buffer (pH 7.5). For the estimation of GSH, catalase, 
total protein and aldose reductase inhibition % activity, the 
lenses were homogenized with 0.1M potassium phosphate 
buffer to 10 volumes and centrifuged at 4000 rpm for 
15 minutes. The supernatant was used for biochemical 
estimations (37).
Biochemical parameters
(a) Estimation of malondialdehyde level
One milliliter of the homogenate was combined with 
2 mL of TCA–TBA–HCl reagent (15% trichloroacetic 
acid and 0.375% thiobarbituric acid in 0.25 N HCl) and 
boiled for 15 minutes. The mixture was then cooled and 
the precipitate was removed after centrifugation at 1000 
rpm for 10 minutes. The absorbance was measured at 535 
nm against a blank without tissue homogenate. The values 
were expressed as nmole/100 mg of tissue (2).
(b) Estimation of reduced glutathione level
One milliliter of 10% homogenate was mixed with 1 ml of 
5% TCA (w/v) and the mixture was allowed to stand for 30 
minutes and centrifuged at 2500 rpm for 15 minutes. 0.5 
mL of supernatant was taken and 2.5 mL of 5,5′-Dithiobis-
(2-nitrobenzoic acid) (DTNB) was added and mixed 
thoroughly. The absorbance was recorded at 412 nm and 
the results were expressed as nmole/100 mg tissue (1).
(c) Estimation of catalase activity
To 0.1 mL of supernatant, 1 mL of phosphate buffer and 
0.4 mL water was added. Reaction was started by adding 
0.5 mL H2O2and the mixture was incubated at 37°C 
for 1 minute. Reaction was stopped by adding 2 mL of 
dichromate: acetic acid reagent and kept in boiling water 
bath for 15 minutes. The mixture was cooled and the 
absorbance was read at 570 nm before and after reaction. 
CAT activity was calculated in terms of U/mg of tissue (38).
(d) Estimation of total protein content
Chemicals required: Reagent I: 48 mL of 2% Na2CO3 in 0.1 
N NaOH, 1 mL of 1% sodium potassium tartrate in H2O, 1 
mL 0.5% CuSO4 in H2O; Reagent II- 1-Part Folin-Phenol [2 
N]: 1- Part water; Bovine Serum Albumin (BSA) standard 
- 1 mg/mL. 0.2 mL of BSA was taken in 5 test tubes and 
volume was made up to 1 mL using distilled water. Then, 
0.2 mL of lens homogenate was taken in a test tube and 
volume was made using 1 mL distilled water. The test tube 
Figure 1. Isolated goat lenses.
Figure 2. Grouping of lenses with 6 lenses in each group.
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with 1 mL distilled water was served as blank. 4.5 mL of 
reagent I was added and incubated for 10 minutes. After 
incubation, 0.5 mL of reagent II was added and incubated 
for 30 minutes. Absorbance was measured at 660 nm 
and a standard graph was plotted, then, the amount of 
protein present in the given sample was estimated from 
the standard graph and expressed as mg/dL (39).
(e) Estimation of aldose reductase inhibition activity %
To 0.1 mL of lens homogenate, 0.7 mL of phosphate 
buffer (0.067M), 0.1 mL of NADPH and 0.1 mL of D 
L-glyceraldehyde (substrate) were added. By addition of 
the substrate, the enzymatic reaction was started. The 
absorbance was recorded at 340 nm for at least 3 minutes 
at 30 seconds intervals using UV spectrophotometer 
against blank (without the substrate DL- glyceraldehyde). 
Aldose Reductase (AR) inhibitory activity was expressed 
as % inhibition activity (40).
Statistical analysis
Data were expressed as mean ± SEM (n = 6). Significant 
difference between groups was determined using one-way 
ANOVA followed by Tukey’s multiple comparison test. P 
< 0.05 was considered as significant. 
Results
The percentage yield of isolated Fucoidan was found to be 
0.65%. The sulfate content in the isolated Fucoidan as per 
barium chloride method was found to be 33%. HPTLC 
studies showed various peaks of fucoidan hydrolysates 
(Figure 3). One of the hydrolysates of Fucoidan with Rf 
value 0.18 (Peak 3) matched with the standard D-glucose 
Rf value (Figure 4). This confirms the presence of 
D-glucose in the isolated Fucoidan.
Photographic study of lenses
Normal lens incubated with artificial aqueous humour 
showed complete transparency (Figure 5A). The lenses 
which were treated with galactose 55 mM showed 
complete opacification (Figure 5B) of the lens when 
compared with normal lenses (Figure 5A). Lenses 
incubated with galactose 55 mM and ascorbic acid (20 
µg/mL) showed almost normal transparency (Figure 5C) 
when compared with cataractous lenses (Figure 5B). The 
lenses incubated simultaneously with galactose 55 mM 
and Fucoidan at a concentration of 20 µg/mL showed 
relatively less opacity (Figure 5D) when compared with 
cataractous lenses (Figure 5B). The lenses incubated with 
galactose 55 mM and Fucoidan at a concentration of 40 
µg/mL showed almost normal transparency (Figure 5E) 
when compared to the cataractous lenses (Figure 5B) and 
the transparency was also found to be comparable to the 
ascorbic acid treated lenses (Figure 5C).
Study of anti-cataract potential of Fucoidan
Table 1 shows the anti-cataract potential of Fucoidan. 
Figure 3. HPTLC Profile of hydrolysates of Fucoidan.
Figure 4. HPTLC profile of standard D-glucose.
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Normal lenses contain high amount of protein, aldose 
reductase inhibition activity % and catalase activity 
compared to cataractous lenses. The MDA was found to 
be the least in the normal lenses (normal control) and 
highest in the cataractous lenses (disease control). The 
lenses treated with Fucoidan 20 and 40 µg/mL, ascorbic 
acid 20 µg/mL (standard) restored the level of protein, 
aldose reductase inhibition and catalase activity whereas, 
reduced the level of MDA.
Effect of Fucoidan on lens MDA
There was a statistically significant increase in the level 
of malondialdehyde in the cataractous lenses (disease 
control) when compared with the normal lenses (normal 
control). Treatment with Fucoidan 20 and 40 µg/mL, 
ascorbic acid-20 µg/mL showed significant reduction 
(P < 0.001) in malondialdehyde level when compared with 
cataractous lenses (disease control).
Effect of Fucoidan on lens GSH level
A statistically significant reduction in GSH level was 
observed in galactose 55 mM treated cataractous lenses 
(disease control). Lenses incubated simultaneously with 
galactose 55 mM and Fucoidan 20 µg/mL showed a 
significant increase (P < 0.01) in the level of GSH when 
compared with cataractous lenses. Lenses which were 
treated with galactose 55 mM and Fucoidan 40 µg/mL 
simultaneously showed a significant increase (P < 0.001) 
in the level of GSH and it was found to be comparable to 
ascorbic acid treated lenses (standard).
Effect of Fucoidan on lens catalase activity
There was a statistically significant decrease in catalase 
activity observed in cataractous lenses (disease control) 
when compared with normal lenses (normal control). 
Treatment with Fucoidan 20 and 40 µg/mL showed 
highly significant increase (P < 0.001) when compared 
with cataractous lenses (disease control). The results were 
comparable to the standard group.
Effect of Fucoidan on total protein content
A statistically significant reduction was observed in the 
level of total protein in cataractous lenses (disease control) 
when compared with normal lenses (normal control). 
Treatment with Fucoidan-20 and 40 µg/mL showed 
significant increase with P < 0.01 and P < 0.05, respectively. 
Treatment with ascorbic acid-20 µg/mL showed a 
significant increase (P < 0.001) in the level of total protein 
when compared with cataractous lenses (disease control). 
Effect of Fucoidan on aldose reductase inhibition activity 
%
There was a statistically significant decrease in aldose 
reductase inhibition activity % in the cataractous lenses 
(disease control) when compared with normal lenses 
(normal control). Lenses which were incubated with 
Fucoidan 20 and 40 µg/mL showed significant increase 
(P < 0.01) in aldose reductase inhibition activity %. 
Treatment with ascorbic acid (standard) showed highly 
significant increase (P < 0.001) in aldose reductase 
inhibition activity % when compared with cataractous 
lenses (disease control).
Discussion
Oxidative stress is known to be a common basic 
mechanism of cataractogenesis. Various studies reported 
the potential of antioxidant agents against cataractogenesis 
in experimental models of cataract. Augmentation of anti-
oxidant defences of the lens has been reported to prevent 
or delay cataract. Galactose induced cataract is the most 
commonly used experimental model. The galactose 
produces a large amount of its reduced form, galactitol 
inside the lens that leads to osmotic stress (41).
The molecular mechanisms which are involved in the 
development of cataract are mainly non-enzymatic 
glycation of eye lens proteins, oxidative stress and 
activated polyol pathway which accelerates the generation 
of reactive oxygen species. The produced reactive oxygen 
species enhance chemical modification of proteins in 
the lens (40). Lipid peroxidation and other oxidative 
degradative processes are the common cause of genesis 
of free radicals and the lens becomes vulnerable to 
oxidative stress. MDA is one of the end products of lipid 
peroxidation which is reported to have major role in 
the development of cataract. Its role in cataractogenesis 
is due to its cross-linking ability. The accumulation of 
oxidised residues in lens proteins and enzymes interfere 
in normal metabolic process which results in disruption 
of intracellular protein matrix and subsequent loss of lens 
transparency (42). In the present study, cataractous lenses 
Table. 1. Anticataract activity of Fucoidan on isolated goat lenses
Groups MDA(nmoles/100 mg)
GSH
(nmoles/100 mg)
Catalase activity
(U/mg of tissue)
Total protein 
content (mg/dL)
Aldose reductase 
inhibition activity %
Normal control 2.45±0.07 52.75±0.84 5.39±0.38 26.86±1.04 25.58±1.14
Disease control 6.39±0.48 a 35.73±1.54 a 3.67±0.39 a 18.19±0.34a 19.95±0.68 a
Ascorbic acid 20 µg/mL 2.64±0.21b 55.46±1.23b 6.24±0.38b 27.1±1.99b 28.3±1.69b
Fucoidan 20 µg/mL 3.28±0.18b 43.22±1.00c 4.90±0.56b 23.39±0.45d 27.24±1.92c
Fucoidan 40 µg/mL 2.04±0.17b 53.90±1.34b 6.04±0.55b 24.67±0.43c 27.21±0.63c
All values are expressed as mean ± SEM; n=6; a P < 0.001 when compared to normal control. bP < 0.001 when compared to disease control, cP < 0.01 
when compared to disease control, c P < 0.05 when compared to disease control. 
Journal of Herbmed Pharmacology, Volume 7, Number 4, October 2018            http://www.herbmedpharmacol.com248 
Ramu et al
were observed to have high levels of MDA suggesting 
ample lipid peroxidation and oxidative stress. Treatment 
with Fucoidan 20 and 40 µg/mL and ascorbic acid-20 µg/
mL showed significant reduction in the MDA level which 
indicates the anti-oxidant potential of Fucoidan. 
Oxidative stress leads to denaturation and aggregation 
of lens proteins which are further observed by lens 
opalescence. CAT and GSH are the important components 
of innate enzymatic defences of the lens. Detoxification of 
significant amounts of hydrogen peroxide is the main role 
of catalase and thereby prevents damage to the membrane 
and biological structures. GSH is reported to preserve the 
integrity of phospholipid bilayer membrane by inhibiting 
lipid peroxidation (3). In the present study, cataractous 
lenses were observed to have high opacity compared to 
normal lenses. They also showed significant reduction in 
the level of total protein, GSH, catalase activity and aldose 
reductase % inhibition. These results are postulated to 
occur as a result of free radicals formation and increased 
oxidative stress. The level of protein, GSH and catalase 
activity was restored with the treatment of Fucoidan 20 
and 40 µg/mL when compared to the cataractous lenses. 
The results obtained with the treatment of Fucoidan were 
dose dependant and comparable with the ascorbic acid 20 
µg/mL treated lenses.
Aldose reductase is considered to be the main factor 
responsible for significant production of polyol (sugar-
induced cataractogenesis) and its accumulation in the lens 
which leads to the development of cataract. Accumulation 
of polyols increases intra-cellular ionic strength in the lens 
that leads to excessive hydration and subsequent loss of 
membrane integrity (43). In the present study, cataract 
lenses showed high activity of aldose reductase which 
could be correlated to polyol accumulation. Treatment 
with Fucoidan 20 and 40 µg/mL significantly decreased 
Aldose reductase activity and reversed the polyol 
accumulation.
Conclusion
From the above results, it is concluded that Fucoidan 
exhibited potential anti-cataract activity against galactose 
induced cataract in isolated goat lenses. In vitro study may 
not directly correlate with the in vivo conditions therefore, 
in vivo studies in animal models are needed for further 
elucidation. However, the present study substantiates the 
claim of anti-cataract potential of Fucoidan, which may be 
correlated to its anti-oxidant property.
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